On Nov 13, major Wall Street analysts update their ratings for $Mirum Pharmaceuticals (MIRM.US)$, with price targets ranging from $50 to $70.
Morgan Stanley analyst Michael Ulz maintains with a buy rating, and adjusts the target price from $59 to $60.
Citi analyst David Lebowitz maintains with a buy rating, and adjusts the target price from $64 to $68.
Baird analyst Brian Skorney maintains with a buy rating, and adjusts the target price from $44 to $50.
Stifel analyst Dae Gon Ha maintains with a buy rating, and adjusts the target price from $66 to $70.
H.C. Wainwright analyst Ed Arce maintains with a buy rating, and maintains the target price at $66.
Furthermore, according to the comprehensive report, the opinions of $Mirum Pharmaceuticals (MIRM.US)$'s main analysts recently are as follows:
Mirum Pharmaceuticals' Q3 financial results surpassed expectations largely due to robust Livmarli sales. Although some revenue was brought forward due to reimbursement dynamics, Livmarli's launch is showing promising growth and is becoming a more significant part of the company's total franchise sales.
Mirum Pharmaceuticals reported solid results that exceeded expectations, primarily due to the performance of Livmarli, prompting a revision of the FY2024 guidance to exceed the upper limit of the prior forecast.
Here are the latest investment ratings and price targets for $Mirum Pharmaceuticals (MIRM.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月13日，多家華爾街大行更新了$Mirum Pharmaceuticals (MIRM.US)$的評級，目標價介於50美元至70美元。
摩根士丹利分析師Michael Ulz維持買入評級，並將目標價從59美元上調至60美元。
花旗分析師David Lebowitz維持買入評級，並將目標價從64美元上調至68美元。
貝雅分析師Brian Skorney維持買入評級，並將目標價從44美元上調至50美元。
斯迪富分析師Dae Gon Ha維持買入評級，並將目標價從66美元上調至70美元。
H.C. Wainwright分析師Ed Arce維持買入評級，維持目標價66美元。
此外，綜合報道，$Mirum Pharmaceuticals (MIRM.US)$近期主要分析師觀點如下：
mirum pharmaceuticals第三季度的財務業績超出了預期，這主要得益於Livmarli強勁的銷售表現。儘管由於報銷動態導致部分營業收入提前確認，但Livmarli的上市顯示出良好的增長趨勢，正成爲公司總特許經營銷售中更重要的一部分。
mirum pharmaceuticals報告了強勁的業績，超出了預期，這主要得益於Livmarli的表現，因此修訂了2024財年的指導，預計將超過之前預測的上限。
以下爲今日5位分析師對$Mirum Pharmaceuticals (MIRM.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
